Labiotech.eu

News and Trends 20 Jun 2017

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Bayer’s and Regeneron’s blockbuster Eylea could be facing serious competition, as Novartis boasts with positive Phase III results for AMD. Novartis has been struggling on the age-related macular degeneration (AMD) market since its Roche-partnered VEGF-A inhibitor Lucentis was outperformed by Eylea from Bayer and Regeneron, which required a less-frequent dosing schedule and was placed at a lower […]

June 20, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 20 Jun 2017

Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma

argenx’s 2015 deal with Leo Pharma for anti-inflammatory antibodies continues to pay off, though it hasn’t been disclosed by how much exactly. Two years ago, Ghent-based argenx and Danish Leo Pharma teamed up to develop antibodies to counter inflammatory diseases in a deal totalling €105M. argenx just received its second preclinical milestone for granting Leo access to […]

June 20, 2017 - 1 minutemin - By Evelyn Warner

Interview 20 Jun 2017

“We’re at a second revolution in cancer therapy” – Experts discuss the Future of Oncology at Refresh

A panel of experts in immuno-oncology discussed the challenges and opportunities to develop therapies that can effectively fight cancer. “I think right now we’re at a second revolution in cancer therapy, which surprisingly is not necessarily driven by technology but perspective, and how we look at cancer,” said Masoud Tavazoie, CEO of Rgenix. His company, based in New York, […]

June 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 19 Jun 2017

Video: “Biotech is still in its Infancy” – Keynote by Boston’s Prominent Biotech VC

We were very excited that David Berry, General Partner at Flagship Pioneering, opened Refresh earlier this month with a keynote on how far biotech has come. David has extensive experience in the biotech field and holds over 200 patents and patent applications. He has co-founded and helped build more than 20 companies during his time at […]

June 19, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 19 Jun 2017

This Company Uses the Human Microbiome to Discover New Disease Mechanisms

A whole new avenue to human health and disease could soon be accessible, thanks to the human tissue microbiome. Vaiomer has found a way to make it possible! Has anyone else ever been unsettled by the idea that the human body hosts about 10 times more microbes than human cells? Although this might seem an […]

June 19, 2017 - 5 minutesmins - By External Contributor

Trevor Baglin XO1 SuperX Virtual Biotech

Interview 19 Jun 2017

Discussing the Virtual Biotech Model with XO1 Co-Founder Trevor Baglin

Academic, entrepreneur and now venture partner Trevor Baglin discusses his successful experience working with the unique model of virtual biotech. Trevor Baglin, along with Jim Huntington and David Grainger, is one of the members of the team behind XO1, a virtual biotech founded in 2013 and acquired by Janssen Pharmaceuticals just two years later […]

June 19, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

Startup Scout 16 Jun 2017

Meet the Swedish Biotech that is Set to Cure a Rare Kidney Disease

This week we visited the Scandinavian summer and had a look at the Swedish biotech Oxthera, which is developing cell- and enzyme-based therapies to treat hyperoxaluria. Mission: Stockholm-based Oxthera is currently advancing two late-stage clinical products for the treatment of primary and secondary hyperoxaluria, a kidney disease that is caused by the build-up of oxalate in plasma […]

June 16, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 15 Jun 2017

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants to compete with the best-selling drug. At the 2017 Annual European Congress of Rheumatology, currently being held in Madrid, Novartis has presented new data showing that Cosentyx (secukinumab) keeps improving symptoms of ankylosing spondylitis after three years of treatment and […]

June 15, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 15 Jun 2017

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech

The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google’s Verily to invest in late-stage drug development. After the former life science branch of famous Index Ventures went solo in 2016 and became Medicxi, the VC was able to raise a huge sum of €210M in its first round to support early-stage, single-asset […]

June 15, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 15 Jun 2017

MRC Technology, now LifeArc, Set to Invest £500M in UK’s Life Sciences

LifeArc will draw funds from royalties of MSD’s successful checkpoint inhibitor Keytruda to invest in life sciences in both academic and business sectors. Born from the UK’s Medical Research Council, MRC Technology is a charity focused on supporting medical scientific research. Today, it becomes LifeArc and starts an ambitious new plan to invest up to […]

June 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Jun 2017

Where to Find the Perfect Mix of International and German Biotechs? Berlin!

Germany’s capital city Berlin is the perfect meeting place for international and German biotech companies. See here why the city has become a hotspot for life sciences research institutions and businesses! “Berlin! Berlin! We’re going to Berlin!” It might be a phrase usually sung by football fans, but maybe it’s time to have it chanted by other […]

June 15, 2017 - 6 minutesmins - By External Contributor

Expert Advice 15 Jun 2017

6 Ways to get Traction as a Biotech Startup

In 1989, Joshua Boger, founder of Vertex Pharmaceuticals, was on a mission to launch a new generation of biotech companies, but he didn’t have much to show. Fortunately, he understood rapidly that a biotech company needs a solid story in order to succeed. In biotech, “your story is your product”: people need to be enthusiastic […]

June 15, 2017 - 6 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Novartis Tops Ophthalmology Blockbuster Eylea in Phase III Trials

Belgian Llama Antibody Developer gets Second Preclinical Milestone from Danish Pharma

“We’re at a second revolution in cancer therapy” – Experts discuss the Future of Oncology at Refresh

Video: “Biotech is still in its Infancy” – Keynote by Boston’s Prominent Biotech VC

This Company Uses the Human Microbiome to Discover New Disease Mechanisms

Discussing the Virtual Biotech Model with XO1 Co-Founder Trevor Baglin

Meet the Swedish Biotech that is Set to Cure a Rare Kidney Disease

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech

MRC Technology, now LifeArc, Set to Invest £500M in UK’s Life Sciences

Where to Find the Perfect Mix of International and German Biotechs? Berlin!

6 Ways to get Traction as a Biotech Startup

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!